NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $190,424 | -36.8% | 24,227 | -19.6% | 0.40% | -14.4% |
| Q2 2023 | $301,119 | +3.0% | 30,142 | -8.5% | 0.47% | +9.1% |
| Q1 2023 | $292,454 | -27.9% | 32,934 | -10.8% | 0.43% | -17.4% |
| Q4 2022 | $405,469 | -33.6% | 36,928 | -21.3% | 0.52% | -13.8% |
| Q3 2022 | $611,000 | -2.1% | 46,915 | -4.7% | 0.60% | +4.5% |
| Q2 2022 | $624,000 | -6.2% | 49,217 | +3.7% | 0.57% | +59.0% |
| Q1 2022 | $665,000 | -51.4% | 47,464 | +0.4% | 0.36% | -24.0% |
| Q4 2021 | $1,369,000 | +13.6% | 47,292 | +17.6% | 0.48% | +17.9% |
| Q3 2021 | $1,205,000 | +92.5% | 40,212 | +70.3% | 0.40% | +75.2% |
| Q2 2021 | $626,000 | – | 23,611 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |